Holen Sie sich die Stockscreener-App
76.29
1.00%
-0.65
Handel nachbörslich:
76.29
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics says MYKORZO launch tops expectations as HCM data draws praise - MSN
A Look At Cytokinetics (CYTK) Valuation After A Strong Multi‑Year Share Price Performance - Yahoo Finance
Cytokinetics’s SWOT analysis: biotech stock faces profitability test By Investing.com - Investing.com South Africa
Cytokinetics’s SWOT analysis: biotech stock faces profitability test - Investing.com
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise - TradingView
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $264,915, According to a Recent SEC Filing - marketscreener.com
Cytokinetics to Hold Annual Meeting of Stockholders - The Manila Times
Cytokinetics (CYTK) R&D EVP exercises options and sells 3,500 shares - Stock Titan
CYTK: MYQORZO outperforms launch targets, with robust uptake, expanding access, and strong pipeline progress - TradingView
CYTK Initiated Coverage by Citigroup -- Price Target Set at $99. - GuruFocus
Cytokinetics Inc stock (US2328281044): pipeline updates keep biotech in focus - AD HOC NEWS
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
GABELLI & Co INVESTMENT ADVISERS INC. Sells 23,900 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM - American Heart Association Journals
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 7,500 Shares of Stock - MarketBeat
Cytokinetics president & CEO Blum sells $584,400 in common stock. By Investing.com - Investing.com Nigeria
Cytokinetics president & CEO Blum sells $584,400 in common stock. - Investing.com
Cytokinetics Inc stock (US2328281044): CLIMB muscle biology symposium adds to MYQORZO launch momentu - AD HOC NEWS
Cytokinetics (CYTK) CEO sells 7,500 shares, holds 400,330 - Stock Titan
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB) - Yahoo Finance
Q2 EPS Estimates for Cytokinetics Raised by HC Wainwright - MarketBeat
1CYTK.MI Stock Price, Quote & Chart | CYTOKINETICS INC (BIT:1CYTK) - ChartMill
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $97 - Moomoo
CYTK Maintained by JP Morgan -- Price Target Raised to $97.00 - GuruFocus
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Investors Purchase High Volume of Call Options on Cytokinetics (NASDAQ:CYTK) - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - MarketBeat
Growth Investors: Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 11% - Yahoo Finance
Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week - Moomoo
Cytokinetics (CYTK) Unveils Positive MYQORZO Data at ESC 2026 Co - GuruFocus
One Bay Area company scored $800 million around its heart drug. Here's another targeting the same condition - The Business Journals
CYTK Maintains by HC Wainwright & Co. -- Price Target Raised to $140 - GuruFocus
Cytokinetics completes $805 million public offering - The Pharma Letter
Cytokinetics presents new data on heart drug aficamten - Investing.com
Cytokinetics presents new data on heart drug aficamten By Investing.com - Investing.com South Africa
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026 - Caledonian Record
Heart drug MYQORZO shows long-term safety as HCM burden detailed - Stock Titan
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech with 35.91% Potential Upside and Groundbreaking Innovations - DirectorsTalk Interviews
Can Myqorzo drive growth for Cytokinetics amid competition? - MSN
Cytokinetics (NASDAQ: CYTK) prices $760.2M common stock sale at $71 - Stock Titan
Cytokinetics closes $805 million stock offering By Investing.com - Investing.com South Africa
Cytokinetics closes $805 million stock offering - Investing.com
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million - The Manila Times
$805M raised as Cytokinetics sells 11.3M shares at $71 each - Stock Titan
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):